←
ShorterLab20,825 posts
ShorterLab avatar

ShorterLab

@ShorterLab

Countering deleterious phase transitions in ALS/FTD, PD, AD, and related disorders @Penn @PennMedicine @bb_upenn @BMBGGUPENN @PGGUPenn @PennNGG @CAMBUpenn

◷ Joined January 2012▧ 1,663 Photos and videos
ShorterLab avatar
ShorterLab@ShorterLab·23h

Msp1, Cdc48, and Hsp104 coordinate quality control of import-impaired mitochondrial β-barrel proteins: cell.com/cell-reports/fullte…

UEFA EURO avatar
⟳ ShorterLab retweeted
UEFA EURO@UEFAEURO·Nov 16

A beautiful England team move finished by Ben White 👏 #NationsLeague

0:23
England avatar
⟳ ShorterLab retweeted
England@England·Nov 16

Jude Bellingham 🤝 Ben White

0:23
QurAlis avatar
⟳ ShorterLab retweeted
QurAlis@QurAlisCo·Nov 16

QurAlis is excited to announce that the FDA has cleared the IND for QRL-201, our lead program for the treatment of ALS. This significant regulatory milestone clears the path for the initiation of our pivotal clinical trial for QRL-201 in the U.S. (CONQUR). We also announced final data from the dose-range finding phase from the ANQUR Phase 1/2 clinical trial of QRL-201 in ALS. Results demonstrated QRL-201 slowed disease progression as measured by ALSFRS-R by 50 percent (p<0.05), and showed statistically significant reductions in NfL and pNfH, biomarkers of axonal damage in ALS. QurAlis plans to initiate the CONQUR pivotal study in the first half of 2027; the ANQUR open-label extended dosing is ongoing in Canada, the UK, and the EU. QRL-201 is a first-in-class, potent antisense oligonucleotide precision therapeutic in development to restore STATHMIN-2 (STMN2) expression in ALS patients with the aim to modify disease progression and improve outcomes. STMN2 is a protein important for muscle innervation that is regulated by TDP-43 and downregulated in the majority of ALS patients. ANQUR is the first human trial exploring the hypothesis that restoration of STMN2 may be a suitable disease-modifying approach in ALS. Read more in our press release bit.ly/4Cafd88 #precisionmedicine #neurodegnerativediseases #neurologicaldiseases #ALS